CL2008002542A1 - Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. - Google Patents

Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.

Info

Publication number
CL2008002542A1
CL2008002542A1 CL2008002542A CL2008002542A CL2008002542A1 CL 2008002542 A1 CL2008002542 A1 CL 2008002542A1 CL 2008002542 A CL2008002542 A CL 2008002542A CL 2008002542 A CL2008002542 A CL 2008002542A CL 2008002542 A1 CL2008002542 A1 CL 2008002542A1
Authority
CL
Chile
Prior art keywords
compounds
pharmaceutical composition
amyloidosis
amyloid
dementia
Prior art date
Application number
CL2008002542A
Other languages
English (en)
Inventor
Teiji Kimura
Noritaka Kitazawa
Toshihiko Kaneko
Nobuaki Sato
Koki Kawano
Koichi Ito
Mamoru Takaishi
Takeo Sasaki
Yu Yoshida
Toshiyuki Uemura
Takashi Doko
Daisuke Shinmyo
Daiju Hasegawa
Takehiko Miyagawa
Hiroaki Hagiwara
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CL2008002542A1 publication Critical patent/CL2008002542A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

COMPUESTOS REPRESENTADOSPOR LA FÓRMULA (I-1), O SUS SALES FARMACOLÓGICAMENTE ACEPTABLES, DONDE X1 Y HET SON COMO SE DEFINE EN LAS REIVINDICACIONES. COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHOS COMPUESTOS O SUS SALES FARMACOLÓGICAMENTEACEPTABLES, EN FORMA DE UN INGREDIENTEACTIVO. USO DE DICHA COMPOSICIÓN FARMACÉUTICA PARA PREVENIR O TRATAR UNA ENFERMEDAD CAUSADA POR AMILOIDE-B, TAL COMO ENFERMEDADDE ALZHEIMER, DEMENCIA, SÍNDROME DE DOWN O AMILOIDOSIS.
CL2008002542A 2007-08-31 2008-08-28 Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis. CL2008002542A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007225045 2007-08-31
JP2008020009 2008-01-31
JP2008123057 2008-05-09

Publications (1)

Publication Number Publication Date
CL2008002542A1 true CL2008002542A1 (es) 2009-01-02

Family

ID=40387302

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002542A CL2008002542A1 (es) 2007-08-31 2008-08-28 Compuestos derivados de imidazolil piridina ligados a un heterociclo mediante un vinilo, moduladores de la actividad de amiloide-beta; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades tales como alzheimer, demencia, sindrome de down o amiloidosis.

Country Status (19)

Country Link
US (1) US9453000B2 (es)
EP (2) EP2559693B1 (es)
JP (1) JP5433418B2 (es)
KR (1) KR20100055456A (es)
CN (1) CN101815713B (es)
AR (1) AR068121A1 (es)
AU (1) AU2008292390B2 (es)
BR (1) BRPI0815773A2 (es)
CA (1) CA2694401C (es)
CL (1) CL2008002542A1 (es)
ES (1) ES2529648T3 (es)
IL (1) IL203778A (es)
MX (1) MX2010002098A (es)
MY (1) MY150507A (es)
NZ (1) NZ583515A (es)
PE (1) PE20090674A1 (es)
TW (1) TW200916469A (es)
WO (1) WO2009028588A1 (es)
ZA (1) ZA201000474B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
US20090124651A1 (en) * 2007-08-31 2009-05-14 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
JP2012501336A (ja) * 2008-08-27 2012-01-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の製造法
CA2894860C (en) 2008-11-19 2018-11-06 Gerhard Koenig Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2012121809A (ja) * 2009-02-26 2012-06-28 Eisai R & D Management Co Ltd 多環式化合物の製造法およびその中間体
JP2012051805A (ja) * 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd テトラヒドロトリアゾロピリジン誘導体の製造方法
EP2401277A1 (en) 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
TW201035101A (en) 2009-02-26 2010-10-01 Eisai R&D Man Co Ltd Nitrogen-containing fused heterocyclic compound
US20100298348A1 (en) * 2009-05-11 2010-11-25 Kim Nicholas Green Method of Decreasing Ubiquitylated Protein Levels
JP5808319B2 (ja) * 2009-05-11 2015-11-10 フォルム ファーマシューティカルズ、インコーポレイテッド アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
CN102574776A (zh) * 2009-07-31 2012-07-11 桑多斯股份公司 ω-氨基-烷酰胺和ω-氨基-烷硫酰胺的制备方法及该方法的中间体
AU2011206635B2 (en) 2010-01-15 2015-01-22 Cellzome Limited Novel substituted triazole derivatives as gamma secretase modulators
MX357676B (es) 2010-05-17 2018-07-18 Forum Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin- 3-il)benzo[b]tiofeno-2-carboxamida monohidratado.
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
AU2014206834B2 (en) 2013-01-17 2017-06-22 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10372396B2 (en) * 2013-02-21 2019-08-06 Lenovo ( Singapore) Pte. Ltd. Discovery and connection to wireless displays
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
BR112019024987A2 (pt) * 2017-06-02 2020-06-16 Xeris Pharmaceuticals, Inc. Formulações de fármaco de molécula pequena resistente à precipitação
CA3086668A1 (en) * 2018-02-05 2019-08-08 Universite De Strasbourg Compounds and compositions for the treatment of pain
JP2022519779A (ja) * 2019-02-07 2022-03-24 アルサテック，インコーポレイテッド エモキシピンの多価誘導体
JP2025541281A (ja) * 2022-12-15 2025-12-18 シトリクス・セラピューティクス・リミテッド 炎症性疾患若しくは望ましくない免疫応答に関連する疾患の治療又は予防に使用するための置換ピリジン
CN118459425B (zh) * 2024-04-29 2025-11-14 南通华祥医药科技有限公司 一种吡咯烷-1-胺-二盐酸盐的制备方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101156A (en) 1965-09-22 1968-01-31 Hickson & Welch Ltd Triazole derivatives and their use as optical whitening agents
FR2314731A1 (fr) 1975-06-19 1977-01-14 Nelson Res & Dev Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4508718A (en) 1984-01-16 1985-04-02 Warner-Lambert Company Cardiotonic and antihypertensive oxadiazinone compounds
DE3689506D1 (de) 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
US4783463A (en) 1985-10-23 1988-11-08 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
FI91754C (fi) 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
FI902321A7 (fi) 1989-05-19 1990-11-20 Eisai Co Ltd Buteenihappojohdannaiset
JPH03206042A (ja) * 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
EP0468054B1 (en) 1990-02-08 1997-05-28 Eisai Co., Ltd. Benzenesulfonamide derivative
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
US5804577A (en) 1995-09-12 1998-09-08 Hoffmann-La Roche Inc. Cephalosporin derivatives
WO1997014417A1 (en) 1995-10-19 1997-04-24 Merck & Co., Inc. Fibrinogen receptor antagonists
PL329875A1 (en) 1996-05-10 1999-04-12 Icos Corp Derivatives of carbolin
WO1998003166A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
JP2001508767A (ja) 1996-12-02 2001-07-03 藤沢薬品工業株式会社 ５―ｈｔ拮抗作用を有するインドール―ウレア誘導体
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
KR20010005792A (ko) 1997-03-31 2001-01-15 다케다 야쿠힌 고교 가부시키가이샤 아졸 화합물, 이의 제조 방법 및 용도
CA2286909A1 (en) 1997-04-16 1998-10-22 Abbott Laboratories 5,7-disubstituted 4-aminopyrido¬2,3-d|pyrimidine compounds and their use as adenosine kinase inhibitors
TW379224B (en) 1997-12-02 2000-01-11 Fujisawa Pharmaceutical Co Urea derivatives
US5985856A (en) 1997-12-31 1999-11-16 University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6048678A (en) * 1998-12-28 2000-04-11 Eastman Kodak Company Protective overcoat coating compositions
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
MXPA01008606A (es) 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
US7053087B1 (en) 1999-03-04 2006-05-30 Cardiome Pharma Corp. Aminocycloalkyl cinnamide compounds for arrhythmia and analgesics and anesthetics
AU2001241128A1 (en) 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
CA2405170A1 (en) 2000-04-24 2001-11-01 Merck Frosst Canada & Co. Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
ATE288898T1 (de) 2000-12-04 2005-02-15 Hoffmann La Roche Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
US7211575B2 (en) 2001-09-13 2007-05-01 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediated diseases
MXPA04002404A (es) 2001-09-14 2004-05-31 Novo Nordisk As Ligandos novedosos para los sitios hisb10zn2+ del hexamero de insulina en estado r.
RU2004118719A (ru) 2001-11-22 2005-03-27 Оно Фармасьютикал Ко., Лтд. (Jp) Производные пиперидин-2-она и фармацевтические композиции, содержащие такие соединения в качестве активного ингредиента
CA2468544A1 (en) 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
ES2325205T3 (es) 2001-12-20 2009-08-28 Bristol-Myers Squibb Company Derivados de alfa-(n-sulfonamido)acetamida como inhibidores beta-amiloides.
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
WO2003062206A2 (en) 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2003074497A1 (en) 2002-03-01 2003-09-12 Pintex Pharmaceutical, Inc. Pin1-modulating compounds and methods of use thereof
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
PL375552A1 (en) 2002-05-22 2005-11-28 Amgen Inc. Vanilloid receptor ligands and their medical applications
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
AU2003247758A1 (en) 2002-06-27 2004-01-19 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
ATE452879T1 (de) 2002-07-12 2010-01-15 Sanofi Aventis Deutschland Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
JP2006518738A (ja) * 2003-02-12 2006-08-17 トランス　テック　ファーマ，インコーポレイテッド 治療薬としての置換アゾール誘導体
CA2521095A1 (en) 2003-04-01 2004-10-21 Plus Chemicals, B.V. Amorphous simvastatin calcium and methods for the preparation thereof
CN1787822A (zh) * 2003-05-14 2006-06-14 托里派因斯疗法公司 化合物及其在调节淀粉样蛋白β中的用途
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
BRPI0417267A (pt) 2003-12-22 2007-04-17 Pfizer derivados de triazol como antagonistas de vasopressina
US20050187277A1 (en) 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
EP1725556A1 (en) 2004-03-09 2006-11-29 Merck & Co., Inc. Hiv integrase inhibitors
BRPI0511504A (pt) 2004-05-26 2008-01-22 Eisai R&D Man Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
JP2008509982A (ja) 2004-08-16 2008-04-03 プロシディオン・リミテッド アリール尿素誘導体
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
AU2006316005A1 (en) 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
JPWO2007058304A1 (ja) 2005-11-18 2009-05-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の塩またはそれらの溶媒和物
MY144960A (en) 2005-11-24 2011-11-30 Eisai R&D Man Co Ltd Morpholine type cinnamide compound
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
PL1992618T3 (pl) 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
JP2010518080A (ja) * 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
CA2686589A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
AU2008250436B2 (en) 2007-05-11 2013-03-28 F. Hoffmann-La Roche Ag Hetarylanilines as modulators for amyloid beta
WO2008156580A1 (en) 2007-06-13 2008-12-24 Merck & Co., Inc. Triazole derivatives for treating alzheimer's disease and related conditions
US20110009392A1 (en) 2007-08-06 2011-01-13 Schering Corporation Gamma secretase modulators
ES2529648T3 (es) 2007-08-31 2015-02-24 Eisai R&D Management Co., Ltd. Compuesto policíclico
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2009126311A1 (en) * 2008-04-11 2009-10-15 The University Of Texas, M.D. Anderson Cancer Center Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
JP2012501336A (ja) 2008-08-27 2012-01-19 エーザイ・アール・アンド・ディー・マネジメント株式会社 シンナミド化合物の製造法
PT2401270E (pt) 2009-02-26 2014-01-20 Glaxo Group Ltd Derivados de pirazole utilizados como antagonistas do receptor ccr4
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
WO2010097372A1 (de) 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin-b1-antagonisten
EP2401277A1 (en) 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
JPWO2010098466A1 (ja) 2009-02-27 2012-09-06 Hoya株式会社 成形型およびプラスチックレンズの製造方法
BR112012000915A2 (pt) 2009-07-15 2019-09-24 Janssen Pharmaceuticals Inc derivados de triazol e imidazol substituídos como moduladores de gama secretase.
US8381014B2 (en) * 2010-05-06 2013-02-19 International Business Machines Corporation Node controller first failure error management for a distributed system

Also Published As

Publication number Publication date
CN101815713B (zh) 2013-09-11
EP2559693A1 (en) 2013-02-20
KR20100055456A (ko) 2010-05-26
EP2181992B8 (en) 2013-06-26
IL203778A (en) 2013-11-28
CA2694401A1 (en) 2009-03-05
JPWO2009028588A1 (ja) 2010-12-02
EP2559693B1 (en) 2014-11-26
EP2181992A4 (en) 2011-09-14
TW200916469A (en) 2009-04-16
MX2010002098A (es) 2010-03-30
AU2008292390A1 (en) 2009-03-05
MY150507A (en) 2014-01-30
EP2181992A1 (en) 2010-05-05
PE20090674A1 (es) 2009-06-19
BRPI0815773A2 (pt) 2019-09-24
WO2009028588A1 (ja) 2009-03-05
ES2529648T3 (es) 2015-02-24
NZ583515A (en) 2011-05-27
CN101815713A (zh) 2010-08-25
AR068121A1 (es) 2009-11-04
AU2008292390B2 (en) 2013-04-04
EP2181992B1 (en) 2013-05-01
US20110009619A1 (en) 2011-01-13
CA2694401C (en) 2012-12-04
JP5433418B2 (ja) 2014-03-05
US9453000B2 (en) 2016-09-27
ZA201000474B (en) 2011-05-25

Similar Documents

Publication Publication Date Title
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
UY30500A1 (es) Compuestos de azabencimidazolilo
UY31189A1 (es) Compuestos heterocíclicos
CR11554A (es) Pirrolo-Pirimidinas y Pirrolo-Piridinas
UY30282A1 (es) Compuestos quimicos
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY35586A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2012000001A1 (es) Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros.
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
LT3133070T (lt) Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui
DK2150530T3 (da) Substituerede sulfonamid-derivater
AR060675A1 (es) Derivados de n-(2-tiazolil)-amida como inhibidores de gsk-3,metodo de preparacion, composiciones farmaceuticas que los contienen,y usos terapeuticos.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31141A1 (es) Compuestos de piperidina y sus usos
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien